Full Press Release Details
New Dupixent (dupilumab) data in patients as young as 6 years old
with moderate-to-severe atopic dermatitis to be presented at WCPD and EADV
PARIS and TARRYTOWN, N.Y. September 21, 2021 - New Dupixent
(dupilumab) analyses in patients as young as 6 years old with moderate-to-severe atopic dermatitis will be presented at the 14th World Congress of Pediatric Dermatology Annual Congress (WCPD) from September 22-25 and the 30th European
Academy of Dermatology and Venereology Congress (EADV) from September 29-October 2.
extensive portfolio of Dupixent data being showcased at these global congresses addresses the impact of Dupixent on the signs, symptoms and quality of life in patients as young as six years old with moderate-to-severe atopic dermatitis and reinforces the need for studying the long-term safety and efficacy of treatments targeting type 2 inflammation, said Naimish Patel, M.D. Head of Global
Development in Immunology and Inflammation at Sanofi. In addition, we look forward to presenting key findings from our global Atopic Dermatitis-GAP survey and Quality of Care Report, which demonstrate
our commitment to disease education and fostering new conversations about best practices for patient care within the atopic dermatitis community
Notable Dupixent presentations include long-term efficacy and safety data showing the impact of Dupixent on signs and symptoms of moderate-to-severe atopic dermatitis in children, adolescents and adults. More than 30 presentations include Dupixent results on skin lesions, itch and skin infections as well
as sleep and health-related quality of life for patients and their families, including in adults with a history of mental health disorders and in children with anxiety and depression. Real-world evidence will be also presented from observational
registries and claims databases across multiple geographies.
Notable disease burden data to be presented at EADV include results from the Atopic Dermatitis Global
Adolescent and Pediatric Survey on how patients, caregivers, and physicians view the full impact of moderate-to-severe atopic dermatitis based on findings from more than
3,900 people across 13 countries. Data will also be shared from the Quality of Care in AD Initiative, which documents best practices from 32 atopic dermatitis centers across the world, focused on the value of patient education and
Data to be presented at WCPD 2021
Clinical Efficacy and Safety of Dupixent in Atopic Dermatitis
Quality of Life Data in
Atopic Dermatitis for Dupixent
Dupixent Use and Vaccination
Abstracts presenting research on the burden of atopic
Data to be presented at EADV 2021
Long-Term Efficacy and Safety of Dupixent in Atopic Dermatitis
Quality of Life Data for Dupixent in Atopic Dermatitis
Additional Efficacy and Safety Analyses of Dupixent in Atopic Dermatitis
Abstracts presenting research on patient education, health-related quality of life and burden of
disease in atopic dermatitis include:
Dupixent is a fully human monoclonal antibody that inhibits the signalling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways. Dupixent is not an immunosuppressant and does not require lab monitoring. IL-4 and IL-13 are key and central drivers of the type 2 inflammation that plays a major role in atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyposis
Dupixent is currently approved in the U.S., Europe, Japan and other countries around the world for use in specific patients with moderate-to-severe atopic dermatitis, as well as certain patients with asthma or CRSwNP in different age populations. Dupixent is also approved in one or more of these
indications in more than 60 countries around the world and more than 300,000 patients have been treated globally.
Dupilumab Development Program
Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement. To date, dupilumab has been studied across 60
clinical trials involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation.
Sanofi and Regeneron are
studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes, including pediatric asthma (6 to 11 years of age, Phase 3), chronic obstructive pulmonary disease with evidence of type 2 inflammation (Phase
3), pediatric atopic dermatitis (6 months to 5 years of age, Phase 3), eosinophilic esophagitis (Phase 3), bullous pemphigoid (Phase 3), prurigo nodularis (Phase 3), chronic spontaneous urticaria (Phase 3), chronic inducible urticaria-cold (Phase
3), chronic rhinosinusitis without nasal polyposis (Phase 3), allergic fungal rhinosinusitis (Phase 3), allergic bronchopulmonary aspergillosis (Phase 3) and peanut allergy (Phase 2). These potential uses of dupilumab are currently under clinical
investigation, and the safety and efficacy in these conditions have not been fully evaluated by any regulatory authority.
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness
with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
Regeneron (NASDAQ: REGN) is a leading
biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability
to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development,
almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions,
infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through our proprietary
VelociSuite technologies, such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious
research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.
additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
Sanofi Media Relations Contacts
Regeneron Media Relations Contact
Tel: +1 914-847-6314
Investor Relations Contacts North America
Tel.: +33 (0)1 53 77 45 45
Investor Relations Contact
Tel: +1 914-847-5443
Sanofi Forward-Looking Statements
release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates
regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words expects , anticipates , believes ,
intends , estimates , plans and similar expressions. Although Sanofi s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking information and statements. These risks
and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the
product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing,
unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and
the impact that COVID-19 will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy
as a whole. Any material effect of COVID-19 on any of the foregoing could also adversely impact us. This situation is changing rapidly and additional impacts may arise of which we are not currently aware and
may exacerbate other previously identified risks. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under Risk Factors
and Cautionary Statement Regarding Forward-Looking Statements in Sanofi s annual report on Form 20-F for the year ended December 31, 2020. Other than as required by applicable law, Sanofi
does not undertake any obligation to update or revise any forward-looking information or statements.
Regeneron Forward-Looking Statements and
Use of Digital Media
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and
the future performance of Regeneron Pharmaceuticals, Inc. ( Regeneron or the Company ), and actual events or results may differ materially from these forward-looking statements. Words such as anticipate,
expect, intend, plan, believe, seek, estimate, variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all
forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the impact of SARS-CoV-2
(the virus that has caused the COVID-19 pandemic) on Regeneron s business and its employees, collaborators, and suppliers and other third parties on which Regeneron relies, Regeneron s and its
collaborators ability to continue to conduct research and clinical programs, Regeneron s ability to manage its supply chain, net product sales of products marketed or otherwise commercialized by Regeneron and/or its collaborators
(collectively, Regeneron s Products ), and the global economy; the nature, timing, and possible success and therapeutic applications of Regeneron s Products and product candidates being developed by Regeneron and/or its
collaborators (collectively, Regeneron s Product Candidates ) and research and clinical programs now underway or planned, including without limitation Dupixent (dupilumab);
the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron s Product Candidates and new indications for Regeneron s Products, such as Dupixent for the treatment of pediatric asthma, chronic
obstructive pulmonary disease with evidence of type 2 inflammation, pediatric atopic dermatitis, eosinophilic esophagitis, bullous pemphigoid, prurigo nodularis, chronic spontaneous urticaria, chronic inducible urticaria-cold, chronic rhinosinusitis
without nasal polyposis, allergic fungal rhinosinusitis, allergic bronchopulmonary aspergillosis, peanut allergy, and other potential indications; uncertainty of the utilization, market acceptance, and commercial success of Regeneron s Products
and Regeneron s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing or any
potential regulatory approval of Regeneron s Products and Regeneron s Product Candidates; the ability of Regeneron s collaborators, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing,
packaging, labeling, distribution, and other steps related to Regeneron s Products and Regeneron s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates; safety issues resulting
from the administration of Regeneron s Products (such as Dupixent) and Regeneron s Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron s Products and Regeneron s
Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron s ability to continue to develop or commercialize Regeneron s Products and
Regeneron s Product Candidates, including without limitation Dupixent; ongoing regulatory obligations and oversight impacting Regeneron s Products, research and clinical programs, and business, including those relating to patient privacy;
the availability and extent of reimbursement of Regeneron s Products from third-party payers, including private payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government
such as Medicare and Medicaid; coverage and reimbursement determinations by such payers and new policies and procedures adopted by such payers; competing drugs and product candidates that may be
superior to, or more cost effective than, Regeneron s Products and Regeneron s Product Candidates; the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators may be replicated
in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to
meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron s agreements with Sanofi, Bayer,
and Teva Pharmaceutical Industries Ltd. (or their respective affiliated companies, as applicable), to be cancelled or terminated; and risks associated with intellectual property of other parties and pending or future litigation relating thereto